Business Wire

SICHUAN-PROVINCIAL

17.11.2022 10:57:35 CET | Business Wire | Press release

Share
Art + Cultural and Creative Products Giving New Life to Cultural Relics

An international themed achievement exhibition of “THE BIG DRAW ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was held at the Sanxingdui Museum on November 16, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116006124/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

“THE BIG DRAW, UK Arts Charity launched ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was co-hosted by Sichuan Provincial Department of Culture and Tourism, Deyang Municipal People’s Government, Sichuan Provincial Cultural Heritage Administration, and Hong Kong Trade Development Council; co-organised by Sichuan Publicity Information Center for Culture and Tourism, Sichuan Provincial Academy of Arts, and Management Committee of Sanxingdui Museum; supported by Sichuan Provincial Cultural Relics and Archaeology Research Institute and Deyang Municipal Bureau of Culture, Radio, TV and Tourism. Since the event was launched in June 2022, it has attracted 33 renowned artists from 22 countries and regions and nearly 2,000 participants from over 80 schools and universities.

Yan Sashuang, Vice Director General of Sichuan Provincial Department of Culture and Tourism, presided over the event of the themed achievement exhibition. Dai Yunkang, Vice Director General of the Publicity Department of the CPC Sichuan Provincial Committee, addressed the event. Dai pointed out that Sichuan is a renowned tourist destination in China for its unique Ba-Shu culture and ancient Shu culture. This event attracted artists, art lovers and children worldwide to portray Sanxingdui in their eyes, breathing new life into cultural relics.

He Ping, vice mayor of Deyang Municipal People’s Government, said this event significantly promoted the creative inheritance of Sanxingdui culture and opened a new chapter in the innovative application of cooperation outcomes.

Jacky Chung, Director of the Chinese mainland of Hong Kong Trade Development Council, pointed out that the event is another proof of the in-depth cooperation between Sichuan’s museums and cultural institutions and Hong Kong-funded enterprises.

Kam Panesar, The Big Draw Brand Ambassador in China said, “The UK's expertise in museum and galleries culture and creative tourism is world class. Together with Sichuan Provisional Bureau for Culture and Tourism is an ingrained part of the UK's Arts & Cultural knowledge to implement people centred cultural and artistic festivals in both the UK and China.”

Sanxingdui Culture and Tourism Development Co., Ltd. and BRDGS Partners Group signed an agreement on cultural and creative products cooperation at the site.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221116006124/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye